Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study

IMPORTANCE: Single-agent immune checkpoint inhibition has not shown activities in advanced refractory colorectal cancer (CRC), other than in those patients who are microsatellite-instability high (MSI-H). OBJECTIVE: To evaluate whether combining programmed death-ligand 1 (PD-L1) and cytotoxic T-lymp...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Eric X., Jonker, Derek J., Loree, Jonathan M., Kennecke, Hagen F., Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L., Wei, Alice C., Magoski, Nadine M., Tu, Dongsheng, O’Callaghan, Chris J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206536/
https://www.ncbi.nlm.nih.gov/pubmed/32379280
http://dx.doi.org/10.1001/jamaoncol.2020.0910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206536/
https://www.ncbi.nlm.nih.gov/pubmed/32379280
http://dx.doi.org/10.1001/jamaoncol.2020.0910

Ejemplares similares